Development of Diagnostic Imaging of Malignant Tumor using New PET Probe AIB

Not Applicable

• Conditions: Malignant neoplasms; D009369

• Registration Number: JPRN-jRCTs031210540
• Lead Sponsor: Tamura Kentaro

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Start: 2022-01-06
• Last Update Posted: 23 April 2024

Recruitment & Eligibility

• Status: ot Recruiting
• Sex: Male
• Target Recruitment: 10

Inclusion Criteria

1. Healthy male subjects aged 20 or older and under 65 at the time of informed consent
2. Subjects who provide written informed consent
3. Subjects with BMI of less than 25

Exclusion Criteria

1. Subjects who have severe or progressive complications.
2. Subjects who have obvious abnormalities in physical and laboratory examinations after obtaining the informed consent
3. Subjects who have past history of severe drug hypersensitivity
4. Subjects with drug or alcohol addiction
5. Subjects who smoke
6. Subjects who have received medication or used vitamins, herbal medicines, or supplements within 14 days prior to their visit
7. Subjects who are claustrophobic
8. Subjects who have undergone an examination with radiation exposure for the purpose of medical treatment (X-ray, CT, PET, DEXA, etc.) within the past 12 months, or for the purpose of research within the past 6 months. Chest X-rays conducted as part of the annual medical check are excluded.
9. Subjects who are considered to be inappropriate to participate in this study.

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Safety of [11C]AIB in human subjects <br>Radiation dosimetry of [11C]AIB in human subjects

Secondary Outcome Measures

Name	Time	Method
Pharmacokinetics of [11C]AIB